LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Point of Care Testing Market Driven by New Molecular Diagnostic Technologies

By LabMedica International staff writers
Posted on 14 Jul 2022
Image: The global POC testing market is expected to surpass USD 70 billion by 2030 (Photo courtesy of Global Market Insights)
Image: The global POC testing market is expected to surpass USD 70 billion by 2030 (Photo courtesy of Global Market Insights)

The global point of care (POC) testing market is projected to reach USD 70.8 billion by 2030, driven by an increasing number of pathology labs and services equipped with advanced diagnostic equipment. Molecular testing technology allows nucleic acid detection directly through amplification and screening of sample. As a result, industry players have been focusing their efforts on developing new POC molecular diagnostic technologies to deliver faster results with high accuracy and specificity. Thus, the introduction of new POC molecular diagnostic technologies that deliver faster results with high accuracy and specificity will positively impact the market growth.

These are the latest findings of Global Market Insights Inc. (Selbyville, DE, USA), a market research and strategy consulting firm.

Based on product, the cardiometabolic testing products segment dominated the global POC testing market with revenue of more than USD 3.6 billion in 2021. Greater affordability and convenience over conventional testing along with the availability of several cardiometabolic testing products is expected to continue driving the segment’s growth. Based on technology, the immunoassay segment accounted for the highest revenue share of 17.7% of the global POC testing market in 2021 and is expected to register a significant CAGR through 2030. Immunoassay is a highly selective bioanalytical technique used to determine the presence or quantity of analytes ranging from micro molecules to macro molecules in a solution. This technique provides quick, cost effective and simple methods for detection with high sensitivity and precise results.

Based on prescription, the home-care settings segment is set to dominate the global POC testing market with revenues surpassing USD 18.2 billion by 2030. This can be attributed to the introduction of several monitoring device and other devices that do not require training for operating. Such devices reduce dependency on professionals and offer owners the liberty to monitor, keep a track of glucose levels and manage diabetes efficiently in their home-care setting. Geographically, the POC testing market in Asia Pacific is projected to register a CAGR of 9.5% over the forecast period, driven by the increasing prevalence of infectious diseases, novel product launches and rising government healthcare expenditure. The European POC testing market is expected to be driven by favorable government initiatives and programs, rapidly evolving POCT techniques for diagnosing infectious diseases, and technological improvements & innovations for more appropriate and rapid testing products in the region.

Related Links:
Global Market Insights Inc. 

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more